|Bid||0.00 x 2200|
|Ask||0.00 x 800|
|Day's Range||96.26 - 98.02|
|52 Week Range||74.14 - 102.17|
|PE Ratio (TTM)||19.58|
|Earnings Date||Jul 25, 2018|
|Forward Dividend & Yield||1.20 (1.19%)|
|1y Target Est||106.57|
NEW YORK, June 15, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Avery ...
Rising expenses and lack of geographic diversification remain major causes of concern for Raymond James (RJF), while strategic acquisitions may provide some support.
New Team - the Twelfth to Join Steward This Year - Will Be Based in Portsmouth, New Hampshire Office PORTSMOUTH, N.H. , May 30, 2018 /PRNewswire/ -- Steward Partners Global Advisory , LLC, an employee-owned, ...
Raymond James (RJF) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Wells Fargo Alum Brings 30-Plus Years of Experience to New Role NEW YORK , May 16, 2018 /PRNewswire/ -- Steward Partners Global Advisory LLC, an employee-owned, full service independent partnership associated ...
Of the 21 analysts covering Charles Schwab (SCHW), eight recommend “strong buy,” five recommend “buy,” seven recommend “hold,” and one recommends “sell.” There were no “strong sell” recommendations.
Office is the Firm's 15th Location Nationwide Advisors Joining from Wells Fargo and Morgan Stanley MORRISTOWN, N.J. , May 15, 2018 /PRNewswire/ -- Steward Partners Global Advisory , LLC, an employee-owned, ...
Charles Schwab (SCHW) has an NTM (next-12-month) price-to-book ratio of 3.8x, higher than competitors’ average ratio of 1.5x. Peers Morgan Stanley (MS), Goldman Sachs (GS), and Raymond James Financial (RJF) have NTM price-to-book ratios of 1.3x, 1.2x, and 2.0x, respectively.
New Team is Steward's Seventh Addition this Year MANCHESTER, N.H. , May 14, 2018 /PRNewswire/ -- Steward Partners Global Advisory , LLC, an employee-owned, full-service independent partnership associated ...
Expanding the presence of Steward Partners in New England PORTSMOUTH, N.H. , May 2, 2018 /PRNewswire/ -- Steward Partners Global Advisory , LLC, an employee-owned, full-service independent partnership ...
Leaders in the restaurant, retailing and financial services industries respond to analysts questions about strategies for success.
His pay is larger than the CEOs at Raymond James, Bloomin' Brands and a half-dozen other bigger companies.
Reversal in trading activities, stable underwriting fees and higher interest rates are expected to support Raymond James' (RJF) Q2 earnings.
Charles Schwab (SCHW) has a price-to-earnings ratio of 20.80x on an NTM (next-12-month) basis, which implies a premium valuation, as the average for competitors is 11.30x. Morgan Stanley (MS), Wells Fargo (WFC), and Raymond James Financial (RJF) have price-to-earnings ratios of 11.26x, 10.55x, and 12.10x, respectively, on an NTM basis.
Charles Schwab’s (SCHW) total expenses excluding interest amounted to $1.4 billion in 1Q18, which implies a rise sequentially and YoY (year-over-year). Charles Schwab’s compensation and benefits expenses amounted to $770 million in 1Q18 compared to $711 million in 4Q17, which implies an 8% increase. Charles Schwab incurred professional services expenses amounting to $156 million in 1Q18, while in 1Q17, it incurred $133 million, a rise of 17%.
Charles Schwab (SCHW) ended 1Q18 with total client assets amounting to $3.3 trillion, a fall compared to 4Q17 but a rise on a year-over-year basis. In 1Q18, the company posted total proprietary mutual funds amounting to $228.4 billion, while in 4Q17, the figure stood at $246.1 billion. This decline was mainly because of a fall in money market funds from $163.6 billion in 4Q17 to $145 billion in 1Q18.
Charles Schwab (SCHW) posted earnings per share (or EPS) of $0.55 in 1Q18, which exceeded expectations by $0.02. Brokerages (XLF) have benefitted from market volatility, as it prompts customers to increase trading activity.
NEW YORK, April 19, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ...
Alexion Pharmaceuticals (ALXN) is one of the leading biotechnology firms. Soliris is approved to treat aHUS (atypical hemolytic uremic syndrome) and PHN (paroxysmal nocturnal hemoglobinuria). Alexion’s latest acquisition of Wilson Therapeutics is a turnaround strategy that’s being implemented to restructure Alexion’s performance and investors’ sentiments in the market.
May.01 -- Kevin Giddis, head of fixed income at Raymond James, Keith Parker, head of U.S. equity strategy at UBS, and Neil Dwane, global strategist at Allianz Global Investors, discuss the Federal Reserve rate hike timeline and yield curve. They speak with Bloomberg's Jonathan Ferro on "Bloomberg Markets: The Open."